Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics (TSE:BCT)
:BCT
RESEARCH TOOLSreports
BCT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$4.33 - C$61.20
Previous CloseN/A
Volume105.15K
Average Volume (3M)9.39K
Market Cap
C$19.51M
Enterprise ValueC$22.37M
Total Cash (Recent Filing)C$13.65M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Jun 11, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 05, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding3,709,437
10 Day Avg. Volume5,420
30 Day Avg. Volume9,389
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$45.76Price Target Upside769.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
BriaCell Therapeutics News
PremiumCompany Announcements
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025
PremiumCompany Announcements
BriaCell Therapeutics Reports Continued Financial Challenges
PremiumCompany Announcements
BriaCell Announces Positive Shareholder Meeting Results
PremiumCompany Announcements
BriaCell Therapeutics Secures $3.05 Million in Public Offering---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe first patient treated in the Phase 1 trial with Bria-OTS achieved resolution of a lung metastasis, showing early effectiveness of the treatment.
Market ExpectationsThe reverse stock split and model update led to an increased price target of $32, showing improved market expectations for the stock.
Treatment EfficacyBria-IMT regimen shows 100% resolution of brain metastasis in breast cancer patient with orbital lesion.
Bears Say
Capital RequirementThe company plans to expand Bria-OTS treatment to other cancer types, indicating a broad potential application for the therapy.
Financial ChallengesThe company is expected to need to raise additional capital, indicating financial challenges that may affect operations.
---
Options Prices
Currently, No data available
---
Ownership Overview
68.55% Insiders
0.19%
Mutual Funds
<0.01% Other Institutional Investors
31.25% Public Companies and
Individual Investors
BCT FAQ
What was BriaCell Therapeutics’s price range in the past 12 months?
BriaCell Therapeutics lowest stock price was C$4.33 and its highest was C$61.20 in the past 12 months.
What is BriaCell Therapeutics’s market cap?
BriaCell Therapeutics’s market cap is C$19.51M.
When is BriaCell Therapeutics’s upcoming earnings report date?
BriaCell Therapeutics’s upcoming earnings report date is Jun 11, 2025 which is in 69 days.
How were BriaCell Therapeutics’s earnings last quarter?
BriaCell Therapeutics released its earnings results on Mar 12, 2025. The company reported -C$3.311 earnings per share for the quarter, missing the consensus estimate of N/A by -C$3.311.
Is BriaCell Therapeutics overvalued?
According to Wall Street analysts BriaCell Therapeutics’s price is currently Undervalued.
Does BriaCell Therapeutics pay dividends?
BriaCell Therapeutics pays a Notavailable dividend of C$0.09 which represents an annual dividend yield of N/A. See more information on BriaCell Therapeutics dividends here
What is BriaCell Therapeutics’s EPS estimate?
BriaCell Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics have?
BriaCell Therapeutics has 3,709,437 shares outstanding.
What happened to BriaCell Therapeutics’s price movement after its last earnings report?
BriaCell Therapeutics reported an EPS of -C$3.311 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.373%.
Which hedge fund is a major shareholder of BriaCell Therapeutics?
Currently, no hedge funds are holding shares in TSE:BCT
---
BriaCell Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$45.76 (769.96% Upside)
C$45.76 (769.96% Upside)
Blogger Sentiment
Bullish
TSE:BCT Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.34%
12-Months-Change
Fundamentals
Return on Equity
-478.64%
Trailing 12-Months
Asset Growth
-17.02%
Trailing 12-Months
Company Description
BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
---
BCT Stock 12 Month Forecast
Average Price Target
C$45.76
▲(769.96% Upside)
Technical Analysis
Best Analysts Covering BCT
1 Year
1 Year Success Rate
3/23 ratings generated profit
1 Year Average Return
-53.97%
reiterated a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 13.04% of your transactions generating a profit, with an average return of -53.97% per trade.
---